Insilico Medicine Posts First Profit, $106.3M Revenue in First Half of 2026

Unite.AI
Read full post
Insilico Medicine, a clinical-stage AI drug discovery company, reported its first profit with $106.3M revenue in H1 2026, mainly from dealmaking rather than product sales. Key deals include collaborations with SK Biopharmaceuticals and Takeda Pharmaceutical, supporting its drug pipeline advancement.

More in Healthcare

UK Is Urged to Overhaul Regulation of AI-Medical Devices

Covered by 2 sources

How a researcher uses Codex and ChatGPT to search for new antimicrobial molecules

Open AI News
Healthcare5 min read

​Digital Finance Needs A New Kind Of Identity For AI-Driven Economies

Forbes